Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73


Protocol for a feasibility study of a cohort embedded randomised controlled trial comparing NEphron Sparing Treatment (NEST) for small renal masses.

Neves JB, Cullen D, Grant L, Walkden M, Bandula S, Patki P, Barod R, Mumtaz F, Aitchison M, Pizzo E, Ranieri V, Williams N, Wildgoose W, Gurusamy K, Emberton M, Bex A, Tran MGB.

BMJ Open. 2019 Jun 11;9(6):e030965. doi: 10.1136/bmjopen-2019-030965.


Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

Méjean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Lechevallier E, Beisland C, Aitchison M, Oudard S, Patard JJ, Theodore C, Chevreau C, Laguerre B, Hubert J, Gross-Goupil M, Bernhard JC, Albiges L, Timsit MO, Lebret T, Escudier B.

N Engl J Med. 2018 Aug 2;379(5):417-427. doi: 10.1056/NEJMoa1803675. Epub 2018 Jun 3.


Discrete-choice experiment to analyse preferences for centralizing specialist cancer surgery services.

Vallejo-Torres L, Melnychuk M, Vindrola-Padros C, Aitchison M, Clarke CS, Fulop NJ, Hines J, Levermore C, Maddineni SB, Perry C, Pritchard-Jones K, Ramsay AIG, Shackley DC, Morris S.

Br J Surg. 2018 Apr;105(5):587-596. doi: 10.1002/bjs.10761. Epub 2018 Mar 7.


Centralising specialist cancer surgery services in England: survey of factors that matter to patients and carers and health professionals.

Melnychuk M, Vindrola-Padros C, Aitchison M, Clarke CS, Fulop NJ, Levermore C, Maddineni SB, Moore CM, Mughal MM, Perry C, Pritchard-Jones K, Ramsay AIG, Shackley D, Vickers J, Morris S.

BMC Cancer. 2018 Feb 27;18(1):226. doi: 10.1186/s12885-018-4137-8.


Contemporary surgical management of renal oncocytoma: a nation's outcome.

Neves JB, Withington J, Fowler S, Patki P, Barod R, Mumtaz F, O'Brien T, Aitchison M, Bex A, Tran MGB; British Association of Urological Surgeons (BAUS).

BJU Int. 2018 Jun;121(6):893-899. doi: 10.1111/bju.14159. Epub 2018 Mar 2.


Surveillance versus ablation for incidentally diagnosed small renal tumours: the SURAB feasibility RCT.

Soomro N, Lecouturier J, Stocken DD, Shen J, Hynes AM, Ainsworth HF, Breen D, Oades G, Rix D, Aitchison M.

Health Technol Assess. 2017 Dec;21(81):1-68. doi: 10.3310/hta21810.


Cascade Fumarate Hydratase mutation screening allows early detection of kidney tumour: a case report.

Chan MMY, Barnicoat A, Mumtaz F, Aitchison M, Side L, Brittain H, Bates AWH, Gale DP.

BMC Med Genet. 2017 Jul 26;18(1):79. doi: 10.1186/s12881-017-0436-1.


Reorganising specialist cancer surgery for the twenty-first century: a mixed methods evaluation (RESPECT-21).

Fulop NJ, Ramsay AI, Vindrola-Padros C, Aitchison M, Boaden RJ, Brinton V, Clarke CS, Hines J, Hunter RM, Levermore C, Maddineni SB, Melnychuk M, Moore CM, Mughal MM, Perry C, Pritchard-Jones K, Shackley DC, Vickers J, Morris S.

Implement Sci. 2016 Nov 25;11(1):155.


Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered.

Stewart GD, Aitchison M, Bex A, Larkin J, Lawless C, Méjean A, Nathan P, Oades G, Patard JJ, Paul J, Ravaud A, Escudier B; Renal Cross Channel Group.

Eur Urol. 2017 Jun;71(6):845-847. doi: 10.1016/j.eururo.2016.10.029. Epub 2016 Nov 1.


Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer.

Powles T, Sarwar N, Stockdale A, Sarker SJ, Boleti E, Protheroe A, Jones R, Chowdhury S, Peters J, Oades G, O'Brien T, Sullivan M, Aitchison M, Beltran L, Worth D, Smith K, Michel C, Trevisan G, Harvey-Jones E, Wimalasingham A, Sahdev A, Ackerman C, Crabb S.

JAMA Oncol. 2016 Oct 1;2(10):1303-1309. doi: 10.1001/jamaoncol.2016.1197.


The small renal mass. Where is the wisdom we have lost in knowledge? Where is the knowledge we have lost in information?

Aitchison M, Tran M.

BJU Int. 2016 Jun;117(6):851-2. doi: 10.1111/bju.13373. No abstract available.


Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients.

Roseweir AK, Qayyum T, Lim Z, Hammond R, MacDonald AI, Fraser S, Oades GM, Aitchison M, Jones RJ, Edwards J.

BMC Cancer. 2016 Mar 16;16:229. doi: 10.1186/s12885-016-2254-9.


Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology.

Valdagni R, Van Poppel H, Aitchison M, Albers P, Berthold D, Bossi A, Brausi M, Denis L, Drudge-Coates L, De Santis M, Feick G, Harrison C, Haustermans K, Hollywood D, Hoyer M, Hummel H, Mason M, Mirone V, Müller SC, Parker C, Saghatchian M, Sternberg CN, Tombal B, van Muilekom E, Watson M, Wesselmann S, Wiegel T, Magnani T, Costa A.

Crit Rev Oncol Hematol. 2015 Aug;95(2):133-43. doi: 10.1016/j.critrevonc.2015.05.014. Epub 2015 Jun 5. Review.


Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer.

Stewart GD, O'Mahony FC, Laird A, Eory L, Lubbock AL, Mackay A, Nanda J, O'Donnell M, Mullen P, McNeill SA, Riddick AC, Berney D, Bex A, Aitchison M, Overton IM, Harrison DJ, Powles T.

Clin Cancer Res. 2015 Sep 15;21(18):4212-23. doi: 10.1158/1078-0432.CCR-15-0207. Epub 2015 May 26.


Translational research will fail without surgical leadership: SCOTRRCC a successful surgeon-led Nationwide translational research infrastructure in renal cancer.

Stewart GD, Riddick AC, Rae F, Marshall C, MacLeod L, O'Mahony FC, Laird A, Alan McNeill S, O'Connor KM, O'Donnell M, Fineron P, McLaren DB, Aitchison M, Oades G, Hair J, Seywright M, Little B, Nairn R, Lamb G, Macleod T, Dunn I, Ramsey A, Campbell R, Leung S, McLornan L, Rahilly M, Wilson I, Pollock AM, Harrison DJ.

Surgeon. 2015 Aug;13(4):181-6. doi: 10.1016/j.surge.2015.03.001. Epub 2015 Apr 30.


Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer.

Stewart GD, O'Mahony FC, Laird A, Rashid S, Martin SA, Eory L, Lubbock AL, Nanda J, O'Donnell M, Mackay A, Mullen P, McNeill SA, Riddick AC, Aitchison M, Berney D, Bex A, Overton IM, Harrison DJ, Powles T.

Eur Urol. 2014 Nov;66(5):956-63. doi: 10.1016/j.eururo.2014.04.007. Epub 2014 May 10.


Reclassification of the Fuhrman grading system in renal cell carcinoma-does it make a difference?

Qayyum T, McArdle P, Orange C, Seywright M, Horgan P, Oades G, Aitchison M, Edwards J.

Springerplus. 2013 Aug 10;2:378. doi: 10.1186/2193-1801-2-378. eCollection 2013.


Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma.

Venugopal B, Ansari J, Aitchison M, Tho LM, Campbell R, Jones RJ.

BMC Urol. 2013 May 21;13:26. doi: 10.1186/1471-2490-13-26.


The epidemiology and risk factors for renal cancer.

Qayyum T, Oades G, Horgan P, Aitchison M, Edwards J.

Curr Urol. 2013 Feb;6(4):169-74. doi: 10.1159/000343534. Epub 2013 Feb 8. Review.


Expression and prognostic significance of Src family members in renal clear cell carcinoma.

Qayyum T, McArdle PA, Lamb GW, Jordan F, Orange C, Seywright M, Horgan PG, Jones RJ, Oades G, Aitchison MA, Edwards J.

Br J Cancer. 2012 Aug 21;107(5):856-63. doi: 10.1038/bjc.2012.314. Epub 2012 Jul 19.


Prospective study of the role of inflammation in renal cancer.

Qayyum T, McArdle PA, Lamb GW, Going JJ, Orange C, Seywright M, Horgan PG, Oades G, Aitchison MA, Edwards J.

Urol Int. 2012;88(3):277-81. doi: 10.1159/000334971. Epub 2012 Feb 23.


Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems.

Lamb GW, Aitchison M, Ramsey S, Housley SL, McMillan DC.

Br J Cancer. 2012 Jan 17;106(2):279-83. doi: 10.1038/bjc.2011.556. Epub 2011 Dec 13.


Is the presence or absence of tumour necrosis a significant predictor of survival in renal cell cancer?

Qayyum T, McArdle PA, Going JJ, Orange C, Seywright M, Aitchison MA, Edwards J.

Urol Int. 2012;88(1):79-83. doi: 10.1159/000332430. Epub 2011 Oct 27.


Management of adults with Wilms' tumor: recommendations based on international consensus.

Segers H, van den Heuvel-Eibrink MM, Pritchard-Jones K, Coppes MJ, Aitchison M, Bergeron C, de Camargo B, Dome JS, Grundy P, Gatta G, Graf N, Grundy P, Kalapurakal JA, de Kraker J, Perlman EJ, Reinhard H, Spreafico F, Vujanic G, Warwick AB; SIOP-RTSG and the COG-Renal Tumour Committee.

Expert Rev Anticancer Ther. 2011 Jul;11(7):1105-13. doi: 10.1586/era.11.76. Review.


Sexual dysfunction in cardiovascular disease.

Morrison D, Aitchison M, Connelly DT, Mair FS.

BMJ. 2011 Jul 26;343:d4437. doi: 10.1136/bmj.d4437. No abstract available.


Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.

Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, Aitchison M, James N, Oliver RT, Mardiak J, Hussain T, Sylvester R, Parmar MK, Royston P, Mulders PF.

Lancet. 2010 Feb 20;375(9715):641-8. doi: 10.1016/S0140-6736(09)61921-8. Epub 2010 Feb 10.


The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer.

Lamb GW, McArdle PA, Ramsey S, McNichol AM, Edwards J, Aitchison M, McMillan DC.

BJU Int. 2008 Sep;102(6):756-61. doi: 10.1111/j.1464-410X.2008.07666.x. Epub 2008 Apr 2.


The longitudinal relationship between the systemic inflammatory response, circulating T-lymphocytes, interleukin-6 and -10 in patients undergoing immunotherapy for metastatic renal cancer.

Ramsey S, Aitchison M, Graham J, McMillan DC.

BJU Int. 2008 Jul;102(1):125-9. doi: 10.1111/j.1464-410X.2008.07466.x. Epub 2008 Mar 11.


Modulation of lamellipodial structure and dynamics by NO-dependent phosphorylation of VASP Ser239.

Lindsay SL, Ramsey S, Aitchison M, Renné T, Evans TJ.

J Cell Sci. 2007 Sep 1;120(Pt 17):3011-21. Epub 2007 Aug 7.


Helen Wingate: pioneering a woman's role in urology.

Ramsey S, Aitchison M.

Scott Med J. 2007 Feb;52(1):43-4.


Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer.

Ramsey S, Lamb GW, Aitchison M, Graham J, McMillan DC.

Cancer. 2007 Jan 15;109(2):205-12.


Treatment for renal cancer: are we beyond the cytokine era?

Ramsey S, Aitchison M.

Nat Clin Pract Urol. 2006 Sep;3(9):478-84. Review.


A case for screening for renal cancer.

Ramsey S, Aitchison M.

BJU Int. 2006 May;97(5):1123. No abstract available.


Is histologic subtype a significant prognostic factor in renal cell carcinoma?

Ramsey S, Aitchison M.

Nat Clin Pract Urol. 2005 Aug;2(8):374-5. No abstract available.


Concurrent presentation of stage I teratoma and stage I renal cell cancer.

White JD, Seywright MM, Aitchison M, Vasey PA.

Acta Oncol. 2005;44(2):174-6. No abstract available.


Partial nephrectomy used to treat renal cell carcinoma arising in a live donor transplant kidney.

Lamb GW, Baxter GM, Rodger RS, Aitchison M.

Urol Res. 2004 May;32(2):89-92.


The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer.

Bromwich EJ, McArdle PA, Canna K, McMillan DC, McNicol AM, Brown M, Aitchison M.

Br J Cancer. 2003 Nov 17;89(10):1906-8.


Surgical correction of trismus in a child with Hecht syndrome.

Lefaivre JF, Aitchison MJ.

Ann Plast Surg. 2003 Mar;50(3):310-4.


Cytoreductive nephrectomy: is it a realistic option in patients with renal cancer?

Bromwich E, Hendry D, Aitchison M.

BJU Int. 2002 Apr;89(6):523-5.


Gene amplification and overexpression of HER2 in renal cell carcinoma.

Latif Z, Watters AD, Bartlett JM, Underwood MA, Aitchison M.

BJU Int. 2002 Jan;89(1):5-9.


How should patients be followed up after radical nephrectomy for renal cell cancer?

Bromwich E, Aitchison M.

BJU Int. 2002 Jan;89(1):1-4. Review. No abstract available.


An assessment of urethral catheter valves.

Woods M, McCreanor J, Aitchison M.

Prof Nurse. 1999 Apr;14(7):472-4.


Supplemental Content

Loading ...
Support Center